|
|
|
|
|
|
Sponsored by: |
Novartis |
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00241137 |
The purpose of this was to evaluate valsartan 320mg compared to valsartan 160 mg in terms of blood pressure reduction in a patient population of mild to moderate hypertensives
Condition | Intervention | Phase |
Hypertension |
Drug: valsartan |
Phase III |
MedlinePlus related topics: | High Blood Pressure |
ChemIDplus related topics: | Valsartan |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment |
Official Title: | A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg |
Estimated Enrollment: | 3236 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
• Male or female age between 18-80 years of age, inclusive
Exclusion Criteria:
Study ID Numbers: | CVAL489H2301 |
First Received: | October 14, 2005 |
Last Updated: | November 13, 2006 |
ClinicalTrials.gov Identifier: | NCT00241137 |
Health Authority: | Canada: Health Canada |
|
|
|